IDEXX Laboratories, Inc. (IDXX): Valuation
TTM figures as of June 30, 2026
IDEXX Laboratories, Inc. trades at 34.9 times trailing earnings and a 3.15% free-cash-flow yield. On P/E that is higher than 4% of its own month-end history back to 2010. The Healthcare median P/E is 22.9.
Earnings yield 2.87%. Shareholder yield 2.96%. ROIC 48.9%. Piotroski F-score 9 of 9. Net debt $771.9M.
198 month-end valuation observations are on file, starting March 2010.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is IDXX cheap versus its own history?
IDEXX Laboratories, Inc. trades at 34.9 times trailing earnings and a 3.15% free-cash-flow yield. On P/E that is higher than 4% of its own month-end history back to 2010. The Healthcare median P/E is 22.9.
What is IDXX's free-cash-flow yield?
IDEXX Laboratories, Inc. currently yields 3.15% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.